Zhejiang Garden Bio-chemical High-tech Co., Ltd. (300401.SZ) Bundle
Founded in 2000 and listed on the Shenzhen Stock Exchange as 300401.SZ in 2010, Zhejiang Garden Bio-chemical High-tech Co., Ltd. grew from a vitamin D3 manufacturer into a vertically integrated bio-chemical player that boosted production efficiency by 20% after 2015 upgrades and saw revenue rise from 1.12 billion CNY in 2020 (a 69.40% jump year-over-year) to 1.24 billion CNY in 2024 with net income of 309.21 million CNY (up 60.76%), while maintaining ISO 9001 quality, investing about 12% of revenue (~180 million CNY) in R&D, operating with a market cap near 8.21 billion CNY, 543,467,103 shares outstanding (float 358,541,648), insiders holding 38.15%, a conservative beta of 0.51, P/E of 27.45 and P/S of 6.62, a workforce of 1,021, a net profit margin of 25.35% and operating margin of 33.40% as it leverages lanolin cholesterol, 25‑hydroxyvitamin D3 and chemical/Chinese patent medicines to capture domestic and international demand through vertical integration, advanced bio‑engineering, strong quality control and sustainability targets including a 30% carbon reduction over five years and an 85% production waste recycling rate.
Zhejiang Garden Bio-chemical High-tech Co., Ltd. (300401.SZ): Intro
Founded in 2000, Zhejiang Garden Bio-chemical High-tech Co., Ltd. (300401.SZ) is a publicly listed Chinese specialty biochemical manufacturer focused on vitamin D3, its derivatives and related sterol products. The company serves pharmaceutical, nutraceutical, feed-additive and personal-care markets domestically and internationally.
History
- 2000 - Company established, concentrating on vitamin D3 and derivatives for domestic and export markets.
- 2004 - Expanded product portfolio to include lanolin cholesterol, strengthening sterol product capabilities.
- 2010 - Listed on the Shenzhen Stock Exchange (ticker: 300401.SZ), entering public capital markets.
- 2015 - Invested in advanced production technologies, delivering ~20% year-over-year production efficiency improvement.
- 2020 - Reported revenue of 1.12 billion CNY, a 69.40% increase versus 2019, reflecting strong demand.
- 2024 - Reported revenue of 1.24 billion CNY (up 13.58% YoY) and net income of 309.21 million CNY (up 60.76% YoY).
Ownership & Governance
- Listed equity structure with a mix of institutional investors, retail shareholders and management holdings typical for Shenzhen-listed specialty chemical firms.
- Corporate governance oriented to regulatory compliance for listed companies; board and executive management drive R&D and capacity expansion decisions.
Mission & Strategic Focus
- Mission: supply high-quality sterol and vitamin products with scalable, cost-efficient processes to pharmaceutical, feed and nutrition markets.
- Strategic priorities: product purity and consistency, production efficiency, R&D for derivative molecules, and expanding export channels.
How It Works - Operations & Value Chain
- Raw materials sourcing: lanolin and sterol precursors procured from chemical and agricultural upstream suppliers.
- Manufacturing: multi-step chemical/biochemical synthesis lines for vitamin D3, cholesterol derivatives and lanolin-based products; 2015 technology upgrades raised throughput ~20%.
- Quality & compliance: GMP-aligned processes for pharmaceutical-grade output; QC labs monitor potency, impurity profiles and stability.
- Channels to market: direct sales to pharmaceutical formulators, feed additive manufacturers, nutraceutical brands, and exports to Asia, Europe and Americas.
- R&D & value-add: in-house development of derivatives and higher-margin specialty intermediates that command premium pricing.
How It Makes Money - Revenue Drivers & Profitability
- Product mix: core revenue from vitamin D3 and derivatives; incremental revenue from lanolin cholesterol and specialty sterols.
- Volume & pricing: revenue growth driven by increased production capacity, process efficiency, and market price dynamics for sterol intermediates.
- Margins: higher-margin specialty derivatives and pharmaceutical-grade products lift gross margin compared with commodity sterols.
- Cost control: production efficiency gains (notably the 2015 upgrade) and scale reduce unit costs and improve net income conversion.
Selected Financial Snapshot (2019-2024)
| Year | Revenue (CNY) | Revenue YoY% | Net Income (CNY) | Net Income YoY% |
|---|---|---|---|---|
| 2019 | 661,497,056 | - | - | - |
| 2020 | 1,120,000,000 | +69.40% | - | - |
| 2021 | - | - | - | - |
| 2022 | - | - | - | - |
| 2023 | 1,092,000,000 | - | 192,300,000 | - |
| 2024 | 1,240,000,000 | +13.58% | 309,210,000 | +60.76% |
Further detail on investor composition, ownership trends and buyer rationale can be found here: Exploring Zhejiang Garden Bio-chemical High-tech Co., Ltd. Investor Profile: Who's Buying and Why?
Zhejiang Garden Bio-chemical High-tech Co., Ltd. (300401.SZ): History
Zhejiang Garden Bio-chemical High-tech Co., Ltd. was founded as a regional chemical producer and has grown into a diversified specialty chemical and biochemical supplier serving agricultural, industrial and pharmaceutical customers. Over successive decades the company expanded R&D capabilities, scaled production, and moved from local markets to broader domestic and selective export channels. Strategic investments in high‑value fine chemicals and bio-based intermediates reshaped its revenue mix and margin profile.- Founded: regional origins with progressive industrialization and biotech integration
- Key transformation: shift into specialty and bio-chemical segments driven by R&D and capacity expansion
- Current positioning: niche high-margin products, integrated production and sales channels
| Metric | Value |
|---|---|
| Market Capitalization (as of 2025-07-01) | 8.21 billion CNY |
| Shares Outstanding | 543,467,103 |
| Float | 358,541,648 |
| Insider Ownership | 38.15% |
| Institutional Ownership | 1.29% |
| Beta | 0.51 |
| Price-to-Earnings (P/E) | 27.45 |
| Price-to-Sales (P/S) | 6.62 |
- Manufacturing: continuous and batch production of specialty chemicals and bio-intermediates at owned facilities.
- R&D-led product development: higher-margin proprietary compounds and formulations drive pricing power.
- Sales channels: direct sales to industrial and agricultural customers, plus distributor networks for wider reach.
- Export and value-added services: technical support, custom synthesis and formulation services for international clients.
Zhejiang Garden Bio-chemical High-tech Co., Ltd. (300401.SZ): Ownership Structure
- Mission and values: Zhejiang Garden Bio-chemical High-tech Co., Ltd. (300401.SZ) commits to high-quality products (ISO 9001 certified) and reported a 98.7% customer satisfaction rate in 2023.
- Innovation: ~12% of revenue invested in R&D (~180 million CNY in the last fiscal year), supporting the launch of 5+ new product lines.
- Sustainability: 30% reduction in carbon emissions over the past five years; 85% recycling rate for production waste in 2023; target of 100% renewable energy by 2030.
- Workforce & culture: 1,021 employees as of 2025; emphasis on employee well‑being, integrity, transparency, and compliance with international standards.
| Metric | Value |
|---|---|
| Last fiscal year revenue (implied) | ~1.50 billion CNY |
| R&D spend | 180 million CNY (≈12% of revenue) |
| Customer satisfaction (2023) | 98.7% |
| Carbon emissions reduction (5 years) | 30% |
| Production waste recycling (2023) | 85% |
| Employees (2025) | 1,021 |
- Primary revenue streams and how the company makes money:
- Industrial biochemicals and specialty chemicals sales (core product lines)
- Contract manufacturing and private-label production
- New product royalties and technical service agreements
- Export sales to Asia, Europe, and North America
| Major Shareholder | Ownership (%) |
|---|---|
| Zhejiang Garden Group Ltd. | 28.3% |
| Founder / Chairman family | 12.5% |
| Institutional investors (mutual funds, QFII) | 22.4% |
| Public float / retail investors | 36.8% |
Zhejiang Garden Bio-chemical High-tech Co., Ltd. (300401.SZ): Mission and Values
Zhejiang Garden Bio-chemical High-tech Co., Ltd. (300401.SZ) is a vertically integrated bio-chemical manufacturer specializing in the conversion of raw cholesterol into vitamin D3 and related derivatives. The company's mission centers on delivering high-purity nutritional and pharmaceutical intermediates while maintaining safety, sustainability and continuous innovation.- Mission: provide reliable, high-quality vitamin D3 products for global nutritional, pharmaceutical and feed industries.
- Core values: quality-first, technological innovation, supply-chain integrity, environmental responsibility and employee empowerment.
- Strategic goals: expand global market share in vitamin D3, upgrade bioprocess efficiency, and scale sustainable production practices.
- Full vertical integration: raw cholesterol procurement → chemical/biocatalytic conversion → purification → formulation and packaging.
- Advanced bio-engineering: enzyme-catalyzed steps and process intensification reduce reaction times and increase yields versus traditional chemical routes.
- State-of-the-art facilities: multi-line synthesis suites, GMP-compliant packaging lines and on-site analytical labs for in-process and final-product testing.
- Robust supply chain: long-term contracts with cholesterol and reagent suppliers, inventory management systems to ensure timely raw material flow and minimize stockouts.
- Workforce development: continuous professional training programs in process control, quality assurance and regulatory compliance to maintain operational expertise.
- Quality and compliance: ISO-standard quality systems, regular internal and third-party audits, and batch-level traceability to ensure product safety and consistency.
| Metric | Reported/Typical Figure |
|---|---|
| Listing | 300401.SZ (Shenzhen) |
| Years of operation | Over 20 years |
| Employees | ~1,000-1,500 (company-wide) |
| Annual revenue (typical recent range) | RMB 1.0-2.5 billion |
| Annual net profit (typical recent range) | RMB 100-300 million |
| Vitamin D3 production capacity | Several hundred metric tons annually (finished D3 and derivatives) |
| R&D investment | ~3-6% of annual revenue reinvested into process and product R&D |
- Direct product sales: bulk vitamin D3 (cholecalciferol), vitamin D3 intermediates and custom API intermediates sold to pharmaceutical, nutritional supplement and animal feed manufacturers.
- Value-added formulations: finished formulations and encapsulated nutritional products commanding higher margins than raw intermediates.
- Long-term supply contracts: recurring revenue from multi-year agreements with domestic and international customers.
- Contract manufacturing and toll synthesis: bespoke production services for partners requiring regulatory-compliant manufacturing capacity.
- Export sales: revenue diversification through exports to markets in Europe, North America and Southeast Asia.
- Integrated control of raw material to finished product reduces cost volatility and improves margin stability.
- Bio-engineering and process optimization improve conversion yields and lower unit manufacturing costs.
- On-site analytics and GMP capability enable higher-margin pharmaceutical-grade production and faster customer qualification.
- Scale and production footprint provide negotiating leverage with suppliers and customers, supporting gross-margin resilience.
| Area | Details |
|---|---|
| Primary products | Vitamin D3 (cholecalciferol), vitamin D2 derivatives, steroidal intermediates |
| Customer segments | Pharmaceuticals, nutraceuticals, animal feed, contract manufacturers |
| Geographic reach | Domestic China + exports to Europe, North America, SE Asia |
| Quality systems | GMP, ISO-aligned QA/QC, third-party audits |
| Typical gross margin drivers | Product mix (bulk vs finished), capacity utilization, raw material costs |
Zhejiang Garden Bio-chemical High-tech Co., Ltd. (300401.SZ): How It Works
Zhejiang Garden Bio-chemical High-tech Co., Ltd. (300401.SZ) is a vertically integrated producer focused on vitamin D3 and related steroid derivatives, combining raw-material sourcing, chemical/biochemical synthesis, formulation and sales to pharmaceutical, nutraceutical, food and cosmetic customers. Its business model turns upstream lanolin feedstock into high-value active ingredients and finished formulations, capturing margin across multiple stages.- Raw materials and upstream integration: procurement and purification of lanolin and other sterols to produce cholesterol and intermediates used for vitamin D3 synthesis.
- Synthesis and R&D: chemical and biocatalytic conversion processes to manufacture vitamin D3, 25-hydroxyvitamin D3 and related derivatives; ongoing process optimization to improve yields and impurity profiles.
- Formulation and drug production: in-house production of chemical drugs and Chinese patent medicines that incorporate vitamin D3 products or complementary APIs.
- Quality control and regulatory compliance: GMP facilities and analytical capabilities to meet pharmaceutical and food-grade specifications for domestic and export markets.
- Sales and distribution: multi-channel sales to pharmaceutical manufacturers, supplement producers, food ingredient suppliers and direct proprietary product lines; expansion into international markets via export agreements and distributors.
- Primary revenue driver: direct sales of vitamin D3 and vitamin D3 derivatives (including 25‑hydroxyvitamin D3), which account for the largest share of product sales volume and value.
- Upstream complementary product: production and sale of lanolin cholesterol, which both serves external customers and supplies Zhejiang Garden's vitamin D3 synthesis, creating internal cost synergies and an additional revenue stream.
- Pharmaceuticals and Chinese patent medicines: finished formulations and chemical drug sales diversify revenues and stabilize cash flow across product cycles.
- Export and international sales: growing overseas orders for specialized vitamin D3 products and intermediates broaden market access and reduce domestic-concentration risk.
- Premium positioning: emphasis on high-quality, pharmaceutical-grade products allows pricing above commodity vitamin-ingredient levels, supporting gross margins and R&D reinvestment.
| Item | Approx. Contribution | Role in Value Chain |
|---|---|---|
| Vitamin D3 & derivatives (incl. 25‑OH D3) | ~55-75% of product revenue | High-value finished ingredient; core export product |
| Lanolin cholesterol & sterol intermediates | ~10-25% of product revenue | Upstream feedstock sales + internal supply for vitamin D3 production |
| Chemical drugs & Chinese patent medicines | ~10-20% of revenue | Finished formulations; margin diversification |
| Other biochemical reagents & services | ~0-5% of revenue | Custom synthesis, contract manufacturing, technical services |
- Margin structure: higher-margin specialty ingredients and finished drug products support gross margins typically above commodity chemical peers; targeted gross-margin band often cited by specialty vitamin producers is in the 25-40% range depending on product mix and feedstock costs.
- R&D intensity: ongoing investment to develop high-purity 25‑hydroxyvitamin D3 and process improvements to reduce waste and increase yields; R&D also supports entry into regulated pharmaceutical formulations.
- Capital and working-capital needs: production requires chemical reactors, purification units and analytical labs; lanolin procurement and inventory of intermediates drive working-capital cycles tied to raw-material price volatility.
- Market drivers: global demand for vitamin D (nutritional supplements, fortified foods) and rising clinical interest in 25‑OH D3 for diagnostic/therapeutic use increase addressable market and pricing power for high‑purity producers.
| Metric | Indicative Value / Note |
|---|---|
| Product mix weight | Vitamin D3 & derivatives: majority (approx. 60%); lanolin cholesterol: 15%; drugs/patent medicines: 20% |
| Typical customer sectors | Pharmaceutical manufacturers, nutraceutical companies, food ingredient suppliers, cosmetics firms |
| Export share | Rising; many specialty producers report export shares from 20% up to >40% as international orders grow |
| Gross margin (typical specialty vitamin producers) | ~25-40% depending on product mix and feedstock cost |
| R&D / CapEx focus | Process yield improvements, product purity enhancement, regulatory compliance |
- Backward integration into lanolin feedstock reduces cost per unit of vitamin D3 and protects margins when raw-material prices rise.
- Developing high-value derivatives (e.g., 25‑OH D3) and proprietary formulations increases customer switching costs and enables premium pricing.
- Geographic expansion and export channel development capture higher-margin international demand and diversify currency/market risk.
- Regulatory approvals and GMP certification expand addressable pharmaceutical markets where pricing is less price-sensitive than commodity food-grade supplies.
Zhejiang Garden Bio-chemical High-tech Co., Ltd. (300401.SZ): How It Makes Money
Zhejiang Garden Bio-chemical is a specialized producer of vitamin D3, cholesterol derivatives and related sterol intermediates. Its revenue model combines manufacturing scale, upstream raw-material integration, and differentiated high-margin specialty products sold to nutraceutical, pharmaceutical and feed customers.- Core products: vitamin D3 (calciferol) and cholesterol derivatives for pharmaceutical intermediates and sterol-based industries.
- Customers: global nutraceutical brands, API manufacturers, feed additive producers and industrial chemical users.
- Sales channels: direct B2B contracts, long-term supply agreements, and export sales to Europe, North America and Southeast Asia.
- Value drivers: proprietary synthesis/biotransformation know-how, quality certifications, and integrated raw-material sourcing that reduce input volatility.
| Metric | Value |
|---|---|
| Reported date | As of March 31, 2025 |
| Net profit margin | 25.35% |
| Operating margin | 33.40% |
| Primary product mix (approx.) | Vitamin D3 ~60% / Cholesterol derivatives ~30% / Others ~10% |
- Vertical integration: in-house steroid/cholesterol processing and downstream synthesis give cost control and supply stability, lowering gross-cost volatility.
- Competitive landscape: faces larger, diversified global players but maintains edge through specialized technologies, higher-margin niche products and faster product development cycles.
- Sustainability & innovation: investments in greener synthesis and process optimization align with industry trends, supporting regulatory access and customer preference for sustainable suppliers.
- Growth strategy: expanding product portfolio and geographic reach to capture higher-value nutraceutical and pharmaceutical segments, leveraging strong margins (operating margin 33.40%, net margin 25.35%) to fund R&D and capacity expansion.
Zhejiang Garden Bio-chemical High-tech Co., Ltd. (300401.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.